Robert W. Baird reissued their hold rating on shares of Stryker Corporation (NYSE:SYK) in a research note published on Friday morning. They currently have a $161.00 target price on the medical technology company’s stock.
A number of other equities research analysts have also weighed in on the company. Zacks Investment Research upgraded Stryker Corporation from a sell rating to a hold rating in a research note on Tuesday, October 24th. Cowen and Company set a $160.00 price target on Stryker Corporation and gave the stock a buy rating in a research note on Friday, October 6th. Royal Bank Of Canada restated a buy rating and set a $155.00 price target on shares of Stryker Corporation in a research note on Monday, October 2nd. SunTrust Banks, Inc. restated a buy rating and set a $161.00 price target on shares of Stryker Corporation in a research note on Monday, October 2nd. Finally, Argus restated a buy rating and set a $160.00 price target on shares of Stryker Corporation in a research note on Tuesday, August 29th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $151.14.
Shares of Stryker Corporation (NYSE:SYK) opened at 159.74 on Friday. The company has a market cap of $59.75 billion, a P/E ratio of 35.66 and a beta of 0.81. The firm has a 50-day moving average of $145.58 and a 200-day moving average of $141.82. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $160.62.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter in the previous year, the firm earned $1.39 earnings per share. The company’s revenue was up 6.1% on a year-over-year basis. Analysts predict that Stryker Corporation will post $6.44 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be given a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is presently 36.32%.
In other news, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the sale, the insider now directly owns 8,983 shares in the company, valued at $1,313,853.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total value of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at $12,909,976.52. The disclosure for this sale can be found here. 7.40% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the company. Coldstream Capital Management Inc. increased its position in shares of Stryker Corporation by 3.7% in the second quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after buying an additional 626 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of Stryker Corporation in the second quarter valued at approximately $1,249,000. JLB & Associates Inc. purchased a new stake in shares of Stryker Corporation in the second quarter valued at approximately $5,090,000. Colonial Trust Advisors increased its position in shares of Stryker Corporation by 56.1% in the second quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after buying an additional 8,426 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Stryker Corporation by 276.9% in the first quarter. JPMorgan Chase & Co. now owns 269,555 shares of the medical technology company’s stock valued at $35,487,000 after buying an additional 198,035 shares in the last quarter. Institutional investors and hedge funds own 74.00% of the company’s stock.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.